Oxygenta Pharmaceutical logo

Oxygenta Pharmaceutical financials: balance sheet, profit and loss, cash flow

BSE: 524636Pharmaceuticals & BiotechnologySmall Cap

OXYGENTA PHARMACEUTICAL LIMITED · Face value ₹10 · Listed Oct 1994
Last close ₹47.96up ₹1.19 (2.54%)

Share price at the BSE close on 28 Oct 2026. Previous close ₹46.77.

28 Oct: open ₹45.85, high ₹48.25, low ₹45.85

52-week range of traded prices to 28 Oct 2026
₹43.00Low, 11 Jun 2026₹71.59High, 12 Aug 2026
Market cap
₹177 Cr2,423rd largest listed
P/E
Lossover the last 12 months
P/B
Net worth zero or below
Dividend yield
Nonein the last 12 months
ROE
Net worth zero or below
ROCE
−15.1%
Debt to equity
Net worth zero or below
Volume, BSE
8,579

Oxygenta Pharmaceutical's financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Oxygenta Pharmaceutical annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
5.4−5.8Mar 1713−4.5Mar 1821−3.321Mar 1914−5.826Mar 20522.948Mar 2161−0.652Mar 2231−1268Mar 2340−3.557Mar 24109−1062Mar 25113−18110Mar 26
Peak revenue ₹113 Cr, year to Mar 2026; lowest ₹5.39 Cr, year to Mar 2017A loss in 9 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
7.4%−141.1%−141.1%−31.1%−10.0%−57.4%7.4%2.4%−23.0%−24.5%−9.1%−13.6%−107.8%−35.2%−15.9%−42.2%5.6%−1.0%−37.3%−8.8%−9.4%−15.6%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue113
  2. Materials and goods−102
  3. Employee costs−7.6
  4. Other expenses−19
  5. Operating profit−15
  6. Depreciation−2.3
  7. Other income+0.3
  8. One-off items0.0
  9. Finance costs−4.8
  10. Profit before tax−22
  11. Tax+4.6
  12. Net profit−18

What the company owns

  • Plant, investments and other assets₹78 Cr
  • Inventory₹29 Cr
  • Receivables₹10 Cr
  • Cash and bank₹2 Cr

What pays for it: net worth and liabilities

  • Borrowings₹110 Cr
  • Owed to suppliers₹49 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Oxygenta Pharmaceutical quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 23 MayJun 2026Twelve monthsFiled 27 Jul
Revenue from operations513211452613140109113135
1317232248593849119128143
Materials and goods bought61016163747233496102117
Employee costs3–111016788
Other expenses4–6511111310161918
Operating profit before depreciation−8−4−2−841−7−10−10−15−8
Operating margin−141.1%−31.1%−10.0%−57.4%7.4%2.4%−23.0%−24.5%−9.1%−13.6%−5.9%
Materials, % of revenue104.5%–78.4%113.6%70.4%78.0%75.8%84.6%88.3%90.4%87.1%
Employee costs, % of revenue53.1%–3.9%4.4%1.4%0.5%3.6%15.1%6.3%6.8%5.6%
Other expenses, % of revenue83.4%–27.6%39.3%20.8%19.0%43.5%24.8%14.6%16.4%13.2%
Depreciation and amortisation11111223222
Operating profit after depreciation−9−5−3−930−9−12−12−18−10
Other income30000000100
Finance costs11112112457
Profit before one-off items and tax−6−6−4−101−1−11−14−14−22−17
One-off items–10421−10000
Profit before tax−6−4−3−630−11−14−14−22−17
0000000−10−4−5−3
Net profit−6−5−3−63−1−12−3−10−18−14
Other comprehensive income––000000011
Total comprehensive income––−3−63−1−12−3−10−17−13
Net margin−107.8%−35.2%−15.9%−42.2%5.6%−1.0%−37.3%−8.8%−9.4%−15.6%−10.1%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2018 they do not, so they are left blank.
Earlier years, Mar 2010 to Mar 2016
₹ croreMar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations2.50.1––2.66.212.4
––––5.910.416.6
Materials and goods bought1.90.0–––2.38.3
Employee costs––––2.53.33.1
Other expenses––––3.44.75.2
Operating profit before depreciation––––−3.3−4.1−4.2
Operating margin––––−127.4%−66.1%−33.5%
Materials, % of revenue–––––37.1%66.7%
Employee costs, % of revenue––––97.5%53.5%24.7%
Other expenses, % of revenue––––130.3%75.5%42.1%
Depreciation and amortisation0.80.80.8–0.92.50.8
Operating profit after depreciation––––−4.2−6.7−5.0
Other income–––0.00.10.0–
Finance costs–––0.00.00.20.5
Profit before one-off items and tax−2.2−1.0−1.0−1.5−4.1−6.9−5.5
One-off items–––−0.2–––
Profit before tax−2.2−1.0−1.0−1.7−4.1−6.9−5.5
Tax––––0.2−0.7–
Net profit−2.2−1.0−1.0−1.7−4.3−6.1−5.5
Net margin−89.2%−1,598.5%––−164.7%−98.0%−44.3%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 23 May
−35−41−38−35−46−20−26−43
Share capital1010101414333737
Reserves−45−51−48−49−60−54−63−80
21264852685762110
171619726348686
4044535974502376
Total assets21193431546383120
1212182229395268
9716925243151
Net debt21264752685762107
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 23 May
−10.8−2.9−5.4−13.02.6−27.8
−10.8−2.8−5.2−13.04.1−27.9
−16.9−4.82.6−3.513.0−13.0
Receivables−1.4−0.1−8.63.21.2−5.6
Inventories−7.94.8−4.4−2.0−6.8−8.9
Payables−3.3−10.317.4−4.06.919.0
Other working capital−4.30.8−1.8−0.711.7−17.5
Tax paid0.00.0−0.20.0−0.20.2
Capital spending6.74.99.64.111.412.9
Free cash flow−17.5−7.9−15.1−17.2−8.8−40.6
−6.7−4.9−9.6−4.1−11.2−14.4
17.87.615.017.18.742.6
Dividends paid0.00.00.00.00.00.0
Shares bought back0.00.00.00.00.00.0
Shares issued0.04.00.029.55.50.0
Net change in cash0.3−0.30.00.00.00.4
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 23 May
Earnings per share−₹5.69−₹4.44−₹3.19−₹5.67₹2.87−₹0.48–−₹1.09−₹2.86−₹4.75
Diluted earnings per share−₹5.69−₹4.44−₹3.19−₹5.67₹2.87−₹0.48–−₹1.04−₹2.86−₹4.75
Book value per share––−₹34.47−₹40.14−₹37.27−₹24.38−₹32.53−₹6.01−₹6.93−₹11.54
Shareholder yield–––––−11.7%0.0%−30.4%−1.9%0.0%
Market cap at the year end (₹ crore)88–––345297294179
Earnings per share is left blank for the year to Mar 2023: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.

Ratios

Standalone, years to March.Oxygenta Pharmaceutical PE ratio and valuation

RatioMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 23 May
Revenue growth138.7%59.3%−33.1%279.3%16.3%−48.8%27.9%175.7%3.4%
Operating profit growth––––−61.6%––––
–9.3%15.2%−7.4%1.7%28.6%10.5%45.0%51.4%
––6.0 pts−22.6 pts9.1 pts27.0 pts−18.1 pts34.5 pts6.4 pts
From the net margin––15.4 pts−17.2 pts8.8 pts60.5 pts−21.9 pts0.8 pts29.3 pts
From asset turnover––−7.1 pts−3.8 pts−0.1 pts−37.9 pts−0.5 pts13.7 pts−18.9 pts
From borrowing––−2.3 pts−1.6 pts0.4 pts4.3 pts4.2 pts20.0 pts−3.9 pts
Return on capital employed–––26.8%−0.7%−42.1%−33.3%−32.2%−26.4%
Cash conversion–––−367.5%–––––
Interest cover–––1.5–––––
Receivable days–911118120681732
Inventory days–1211001215618214978105
Payable days–20319013940311249113174
Cash conversion cycle, days–−73−79−724−9−32−18−37
Working capital days–−133−231−42045−13−48−8
Asset turnover–0.970.691.981.860.730.681.501.12
Assets per rupee of net worth–−0.60−0.52−0.67−0.90−1.06−1.77−3.19−2.96
Sales per rupee of plant–1.721.203.193.031.111.352.972.37
Capital spending to depreciation–––5.643.114.701.546.395.54
Plant being built, % of plant in use–0.0%0.0%4.0%1.7%––0.6%0.0%
Interest cover is left blank for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020, Mar 2022, Mar 2023, Mar 2024, Mar 2025 and Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. Revenue growth is left blank for the year to Mar 2017: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. Debt to equity is left blank for the years to Mar 2019, Mar 2020, Mar 2021, Mar 2022, Mar 2023, Mar 2024, Mar 2025 and Mar 2026: net worth is below zero, so there is no shareholders' money to set the borrowings against. Return on capital employed is left blank for the years to Mar 2019 and Mar 2020: net worth and borrowings together come to nought or less, so there is no money employed to set the operating profit against. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
−17.4%
Measure10 years5 years3 years
Revenue growth, yearly rate–16.8%53.9%
Return on equity, average–27.4%35.6%
Return on capital employed, average–−26.9%−30.6%
Operating margin, average−30.0%−13.5%−15.7%
Net margin, average−26.7%−14.4%−11.3%
Asset turnover, average–1.171.10
Cash conversion cycle, days, average–−14−29

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−47−38−28
Cash from investing−44−30−14
Cash from financing916843
Capital spending432813
Dividends paid000
Shares bought back000
Shares issued for cash39350
Borrowings raised1018047
Borrowings repaid38380

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–714242
Altman Z-scorePublished threshold 1.81––0.20−1.30−0.680.67−0.15
Beneish M-scorePublished threshold −1.78–1.78−1.929.450.64−2.00−1.12
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–77.5722.268.1423.26−2.2624.27
Receivables growth less revenue growthOur threshold 0 percentage points15.400.75−37.18745.89−55.48−206.4593.33
Inventory growth less cost-of-goods growthOur threshold 0 percentage points−17.1449.75−68.79110.97−25.54−138.1837.55
Other current assets growth less revenue growthOur threshold 5 per cent of revenue−2.560.84−2.458.35−0.272.094.09
Assets under construction, years of additionsOur threshold 2 years of additions0.000.110.07––0.030.00
Effective tax ratePublished threshold 17.16 per cent–6.80–––––
A threshold marked as ours has no published figure; it is the line we read the check against.